Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2018.00449/full |
| _version_ | 1818559074237677568 |
|---|---|
| author | Xiaoxuan Li Xuefei Huang Chongfei Bai Chongfei Bai Dalian Qin Shousong Cao Qibing Mei Yun Ye Yun Ye Jianming Wu |
| author_facet | Xiaoxuan Li Xuefei Huang Chongfei Bai Chongfei Bai Dalian Qin Shousong Cao Qibing Mei Yun Ye Yun Ye Jianming Wu |
| author_sort | Xiaoxuan Li |
| collection | DOAJ |
| description | Background: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemic controlled.Methods: A search of PubMed, Medline, Embase, and The Cochrane Library during 2000.01–2018.03 was performed for randomized controlled trials of teneligliptin compared to placebo in patients with T2DM with monotherapy or add-on treatment.Results: Ten trials with 2119 patients were analyzed. Teneligliptin produced absolute reductions in glycated hemoglobin A1c (HbA1c) levels (weighted mean difference (WMD) 0.82%, 95% confidence interval (CI) [−0.91 to −0.72], p < 0.00001) compared with placebo. However, after 36–42 weeks of follow-up (open-label), HbA1c level rise higher than duration (double-blind) in teneligliptin group. Teneligliptin led to greater decrease of fasting plasma glucose (FPG) level (vs. placebo, WMD −18.32%, 95% CI [−21.05 to −15.60], p < 0.00001). Teneligliptin also significantly decreased the 2 h post-prandial plasma glucose (2 h PPG) (WMD −46.94%, 95% CI [−51.58 to −42.30], p < 0.00001) and area under the glucose plasma concentration-time curve from 0 to 2 h (AUC0−2h) for PPG (WMD −71.50%, 95% CI [−78.09 to −64.91], p < 0.00001) compared with placebo. Patients treated with teneligliptin achieved increased homeostasis model assessment of β cell function (HOMA-β) with 9.31 (WMD, 95% CI [7.78–10.85], p < 0.00001). However, there was no significant difference between teneligliptin and placebo in overall adverse effects (0.96 risk ratio (RR), 95% CI [0.87, 1.06], p = 0.06). The risks of hypoglycemia were not significantly different between teneligliptin and placebo (1.16 RR, 95% CI [0.59, 2.26], p = 0.66).Conclusions: Teneligliptin improved blood glucose levels and β-cells function with low risk of hypoglycemia in patients with T2DM. Common adverse effects of teneligliptin including hypoglycemia were identified and reviewed. Risks of cardiovascular events are less certain, and more data for long-term effects are needed. |
| first_indexed | 2024-12-14T00:20:37Z |
| format | Article |
| id | doaj.art-aa4c4399352a4466a4783eb32ffd7f38 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T00:20:37Z |
| publishDate | 2018-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-aa4c4399352a4466a4783eb32ffd7f382022-12-21T23:25:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-05-01910.3389/fphar.2018.00449363180Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsXiaoxuan Li0Xuefei Huang1Chongfei Bai2Chongfei Bai3Dalian Qin4Shousong Cao5Qibing Mei6Yun Ye7Yun Ye8Jianming Wu9Laboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Chinese Materia Medica, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaLaboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Cancer Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, Affiliated Hospital of Southwest Medical University, Luzhou, ChinaLaboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaBackground: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemic controlled.Methods: A search of PubMed, Medline, Embase, and The Cochrane Library during 2000.01–2018.03 was performed for randomized controlled trials of teneligliptin compared to placebo in patients with T2DM with monotherapy or add-on treatment.Results: Ten trials with 2119 patients were analyzed. Teneligliptin produced absolute reductions in glycated hemoglobin A1c (HbA1c) levels (weighted mean difference (WMD) 0.82%, 95% confidence interval (CI) [−0.91 to −0.72], p < 0.00001) compared with placebo. However, after 36–42 weeks of follow-up (open-label), HbA1c level rise higher than duration (double-blind) in teneligliptin group. Teneligliptin led to greater decrease of fasting plasma glucose (FPG) level (vs. placebo, WMD −18.32%, 95% CI [−21.05 to −15.60], p < 0.00001). Teneligliptin also significantly decreased the 2 h post-prandial plasma glucose (2 h PPG) (WMD −46.94%, 95% CI [−51.58 to −42.30], p < 0.00001) and area under the glucose plasma concentration-time curve from 0 to 2 h (AUC0−2h) for PPG (WMD −71.50%, 95% CI [−78.09 to −64.91], p < 0.00001) compared with placebo. Patients treated with teneligliptin achieved increased homeostasis model assessment of β cell function (HOMA-β) with 9.31 (WMD, 95% CI [7.78–10.85], p < 0.00001). However, there was no significant difference between teneligliptin and placebo in overall adverse effects (0.96 risk ratio (RR), 95% CI [0.87, 1.06], p = 0.06). The risks of hypoglycemia were not significantly different between teneligliptin and placebo (1.16 RR, 95% CI [0.59, 2.26], p = 0.66).Conclusions: Teneligliptin improved blood glucose levels and β-cells function with low risk of hypoglycemia in patients with T2DM. Common adverse effects of teneligliptin including hypoglycemia were identified and reviewed. Risks of cardiovascular events are less certain, and more data for long-term effects are needed.http://journal.frontiersin.org/article/10.3389/fphar.2018.00449/fullteneligliptindipeptidyl peptidase-4 (DPP-4) inhibitortype 2 diabetes mellitus (T2DM)systematic reviewglycemic control |
| spellingShingle | Xiaoxuan Li Xuefei Huang Chongfei Bai Chongfei Bai Dalian Qin Shousong Cao Qibing Mei Yun Ye Yun Ye Jianming Wu Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Frontiers in Pharmacology teneligliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes mellitus (T2DM) systematic review glycemic control |
| title | Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| title_full | Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| title_short | Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| title_sort | efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus a systematic review and meta analysis of randomized controlled trials |
| topic | teneligliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes mellitus (T2DM) systematic review glycemic control |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2018.00449/full |
| work_keys_str_mv | AT xiaoxuanli efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xuefeihuang efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chongfeibai efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chongfeibai efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT dalianqin efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT shousongcao efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT qibingmei efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yunye efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yunye efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jianmingwu efficacyandsafetyofteneligliptininpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |